Skip to content
Disclosery

Nextech Invest Ltd.

Follow

13F filer, CIK 1911010, Zurich, Switzerland

Nextech Invest Ltd. reported $330,025,197 across 14 holdings for the quarter ended 2023-09-30, in a 13F-HR filed 2023-11-14. Its ten largest share positions make up 97.93% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001104659-23-117490

Period
2023-09-30
Reported value
$330M
Holdings
14
Top 10 weight
97.93%
New
1
Sold out
0

Largest buys vs the previous quarter

SecurityShares changeApprox. value
TNGXnew+5,533,980$62.3M
RLAYadded+247,750$2.08M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
PMVPreduced-50,000-$307K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2023

Share positions as resolved from 13F-HR 0001104659-23-117490, largest first. % of portfolio is the value over $330,025,197, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 4,839,529 shares; 2023Q2: 4,839,529 shares; 2023Q3: 4,839,529 shares 4,839,529$134M40.59%0Timeline
TNGXTANGO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: not reported; 2023Q2: not reported; 2023Q3: 5,533,980 shares 5,533,980$62.3M18.88%newTimeline
TYRATYRA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 2,518,582 shares; 2023Q2: 2,518,582 shares; 2023Q3: 2,518,582 shares 2,518,582$34.7M10.51%0Timeline
EQRX INCEQRX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 13,104,424 shares; 2023Q2: 13,104,424 shares; 2023Q3: 13,104,424 shares 13,104,424$29.1M8.82%0
ORICORIC PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: not reported; 2023Q2: 4,285,714 shares; 2023Q3: 4,285,714 shares 4,285,714$25.9M7.86%0Timeline
CGEMCULLINAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 1,221,145 shares; 2023Q2: 1,221,145 shares; 2023Q3: 1,221,145 shares 1,221,145$11.1M3.35%0Timeline
RLAYRELAY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 625,485 shares; 2023Q2: 948,659 shares; 2023Q3: 1,196,409 shares 1,196,409$10.1M3.05%+247,750Timeline
SPRYARS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 1,910,029 shares; 2023Q2: 1,910,029 shares; 2023Q3: 1,910,029 shares 1,910,029$7.22M2.19%0Timeline
ARVNARVINAS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 287,251 shares; 2023Q2: 287,251 shares; 2023Q3: 287,251 shares 287,251$5.64M1.71%0Timeline
KINNATE BIOPHARMA INCKINNATE BIOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 2,329,480 shares; 2023Q2: 2,329,480 shares; 2023Q3: 2,329,480 shares 2,329,480$3.26M0.99%0
PMVPPMV PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 521,284 shares; 2023Q2: 471,284 shares; 2023Q3: 421,284 shares 421,284$2.59M0.78%-50,000Timeline
KRONOS BIO INCKRONOS BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 1,451,537 shares; 2023Q2: 1,451,537 shares; 2023Q3: 1,451,537 shares 1,451,537$1.89M0.57%0
THESEUS PHARMACEUTICALS INCTHESEUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 611,310 shares; 2023Q2: 611,310 shares; 2023Q3: 611,310 shares 611,310$1.64M0.5%0
CCCCC4 THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2021Q4: restricted; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: restricted; 2023Q1: 375,857 shares; 2023Q2: 375,857 shares; 2023Q3: 375,857 shares 375,857$699K0.21%0Timeline

How Q3 2023 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001104659-23-117490 base2023-11-14acceptance time not in the bulk data set